See also: U.S. Guidelines for HIV Testing, Prevention, and Treatment; Starting HIV Treatment; Changing HIV Treatment Regimens; Salvage Treatment for HIV; and Comparing HIV Drug Regimens
Selected Recent Articles
- ViiV Begins Phase III Trial of Two-Drug HIV Regimen. (August 2016, Poz)
- AIDS 2016: Undetectable with long-acting, user-friendly injectable HIV medications. (August 2016, Beta Blog)
- Can a Two-Drug Treatment Regimen Keep HIV Under Control? (August 2016, Beta Blog)
- Four-Day-Per-Week Treatment Maintains HIV Control for 48 Weeks. (August 2016, TheBodyPro)
- Once-Daily Raltegravir and Dolutegravir-Based Dual-Drug Regimen Show Promise. (August 2016, TheBodyPro)
- HIV Cure Research Strategies. (July 2016, TheBodyPro)
- Nanoparticles containing dolutegravir demonstrate efficacy for PrEP delivery. (July 2016, Healio)
- Dolutegravir plus lamivudine dual therapy works well as initial HIV treatment. (July 2016, AIDSmap); related coverage from MedPage Today
- Long-acting injectable drugs work well for HIV maintenance therapy. (July 2016, AIDSmap)
- Experimental Therapy Fails to Stop Viral Rebound Post-HIV Treatment Interruption. (July 2016, Poz)
- Abbreviated ART passes phase 2/3 noninferiority trial in adolescents. (July 2016, Healio)
- Strategies for simplifying ART regimens hold ‘considerable promise.’ (June 2016, Healio)
- Injectable antiretrovirals: The future of HIV management? (June 2016, Healio)
- Maintenance regimen of injected cabotegravir + rilpivirine advances through study. (April 2016, Project Inform)
- CTLs: Stormtroopers of the Immune System. (March 2016, amfAR)
- Dose-finding trials of antibody-based drugs for HIV prevention will start soon. (February 2016, AIDSmap)
- Injectable long-acting cabotegravir shows promise as PrEP in early safety trial. (February 2016, Poz); felated coverage from AIDSmap and abstract from 2016 Retrovirus Conference
- Innovations in antiretroviral therapy delivery. (February 2016, Retrovirus Conference)
- Long-acting injectable cabotegravir + rilpivirine works well as HIV maintenance therapy. (February 2016, AIDSmap); related coverage from Poz and TheBody)
- The HIV latent reservoir: Obstacles and strategies to a cure. (February 2016, Retrovirus Conference)
- Tivicay/lamivudine regimen more cost-effective than standard ART. (January 2016, Healio)
- It’s OK for HIV Salvage Regimens to Nix Nukes. (January 2016, Poz)
- HIV salvage regimens can safely omit NRTIs, says US study. (January 2016, AIDSmap)
- Switching to Two-Drug HIV Regimen Would Save Big Money. (December 2015, Poz)
- Two-drug ART with dolutegravir-lamivudine would be cost-effective and achieve substantial cash savings. (December 2015, AIDSmap)
- Another Two-Drug HIV Regimen Shows Promise. (December 2015, Poz)
- Two-drug maintenance therapy keeps viral load suppressed and may even have advantages over traditional ART. (November 2015, AIDSmap)
- First Studies Spur Confidence in New Ways to PrEP. (October 2015, Beta Blog)
- Why Dolutegravir Might Get Us Closer to Ending AIDS: Next Step, Further Research. (October 2015, HIV i-Base)
- Can dolutegravir dual therapy or monotherapy produce and maintain HIV suppression? (October 2015, AIDSmap)
- Remarkable Results With Dolutegravir Monotherapy. (October 2015, HIV i-Base)
- Rilpivirine + darunavir HIV maintenance regimen matches standard three-drug antiretroviral therapy. (September 2015, AIDSmap)
- Maintenance HIV regimen of rilpivirine and boosted darunavir as effective as three-drug treatment in early results. (July 2015, Project Inform.
- Effective Two-Drug HIV Regimen Sets Stage for Long-Acting Treatment. (April 2015, Poz)
- Cabotegravir and rilpivirine effective for HIV maintenance therapy at 96 weeks. (March 2015, AIDSmap)
- HIV maintenance regimen of cabotegravir and rilpivirine looks promising. (March 2015, Project Inform)
- BREATHER Study’s novel dosing regimen of 5 days on/2 days off controls HIV levels in young people. (March 2015, Project Inform)
- Abbreviated ART noninferior to continuous ART in children with HIV. (February 2015, Healio)
- Financial Incentives for Undetectable Viral Load Are Well Received. (December 2014, Poz)
- Protease inhibitor monotherapy: darunavir/ritonavir less effective than three-drug therapy. (November 2014, AIDSmap)
- Viral Rebound Is Significantly Delayed Among Some Who Interrupt HIV Treatment. (October 2014, TheBodyPro)
- Janssen and ViiV Team Up for New Single-Tablet HIV Regimen. (June 2014, Poz)
- Isentress + Prezista Is Safe, Effective as First-Line HIV Therapy. (March 2014, Poz)
- Early Trial Paves the Way for Study of Long-Acting HIV Meds. (March 2014, Poz)
- Long-Acting HIV Drugs for Maintenance and PrEP. (March 2014, Beta Blog)
- 3 Regimens Hold HIV in Check Without Efavirenz. (March 2014, MedPage Today)
- Novel two-drug maintenance combination works at least as well as triple therapy: stage set for long-lasting injectable formulation. (March 2014, AIDSmap)
- Raltegravir plus boosted darunavir shown to be safe and effective for first-line ART. (March 2014, AIDSmap)
- Trial Bodes Well for Long-Acting HIV Drugs. (March 2014, MedPage Today)
- Building a Better HIV Drug: Nano-Formulated Medicines. (December 2013, TheBodyPro)
- Long-Acting HIV Drugs Could Extend Lives of Low Adherers. (November 2013, Poz)
- Once-daily raltegravir effective as maintenance therapy. (October 2013, AIDSmap)
- New HIV Drug Class Shows Promise. (October 2013, Poz)
- Kaletra and Epivir Dual Therapy Works as Well as Triple Combo. (October 2013, Poz)
- Future HIV care will include both novel antiretroviral drugs and new treatment strategies. (October 2013, AIDSmap)
- Dual therapy with Kaletra and 3TC works well regardless of viral load. (October 2013, AIDSmap)
- Long-Acting HIV Antiretrovirals May Be Revolutionary. But Will They Be Worth It? (October 2013, TheBodyPro)
- Targeting Reactivated HIV Using Natural Killer Cells: Another Potential Cure Strategy. (September 2013, TheBodyPro)
- Once-a-Month HIV Meds Show Promise in Early Trial. (July 2013, Poz)
- Studies look at bone changes during second-line therapy, fractures, and HIV- and HCV-related bone loss. (July 2013, AIDSmap)
- Kaletra monotherapy achieves ‘satisfactory’ levels of HIV suppression during pregnancy. (June 2013, AIDSmap)
- Can people with resistant HIV omit NRTIs when switching from a failing regimen? (March 2013, AIDSmap)